Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Hull

Showing results (121-130 of 147) with videos related to

Pageof 15
Sort By:
Plos One|March 22, 2019
Missed opportunities for earlier diagnosis of HIV in British Columbia, Canada: A retrospective cohort studyNi Gusti Ayu Nanditha, Martin St-Jean, Hiwot Tafessu, et al.
BMC Health Services Research|February 13, 2025
Scaling up hepatitis C testing and linkage-to-care among people who use drugs: lessons learned from a pilot project implemented at a supervised consumption siteAlannah Hannigan, Nandini Krishnan, Kirti Singh, et al.
Prostate Cancer and Prostatic Diseases|December 24, 2002
Combination gene therapy with adenoviral vector-mediated HSV-tk+GCV and IL-12 in an orthotopic mouse model for prostate cancerY Nasu, C H Bangma, G W Hull, et al.
BMC Infectious Diseases|March 1, 2017
Changes in mortality rates and causes of death in a population-based cohort of persons living with and without HIV from 1996 to 2012Oghenowede Eyawo, Conrado Franco-Villalobos, Mark W Hull, et al.
Plos One|March 17, 2026
Beyond direct-acting antiviral therapy: Characterizing mental health conditions and depressive symptoms among patients recently treated for hepatitis CSarah E Kelly, Adedayo Ajidahun, Shannon Bytelaar, et al.
Gene Therapy|August 6, 1999
Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic modelY Nasu, C H Bangma, G W Hull, et al.
AIDS (London, England)|April 5, 2019
Trends in cause-specific mortality in HIV-hepatitis C coinfection following hepatitis C treatment scale-upNadine Kronfli, Sahir R Bhatnagar, Mark W Hull, et al.
Plos One|September 7, 2019
Inflammatory biomarker levels over 48 weeks with dual vs triple lopinavir/ritonavir-based therapy: Substudy of a randomized trialDarrell H S Tan, Maria Jose Rolon, Maria Ines Figueroa, et al.
Journal of the International AIDS Society|September 15, 2016
Effects of a switch from tenofovir- to abacavir-based antiretroviral therapy, with or without atazanavir, on renal functionSilvia A Guillemi, Sean H Ling, Julia S Dahlby, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|March 11, 2022
Prevalence and incidence of hepatitis C infection amongst men who have sex with men in a population-based pre-exposure prophylaxis program in British Columbia, CanadaKyle A Thompson, Gabriel Blank, Junine Toy, et al.
Pageof 15

Showing results (121-130 of 147) with videos related to

Sort By:
Pageof 15
Plos One|March 22, 2019
Missed opportunities for earlier diagnosis of HIV in British Columbia, Canada: A retrospective cohort studyNi Gusti Ayu Nanditha, Martin St-Jean, Hiwot Tafessu, et al.
BMC Health Services Research|February 13, 2025
Scaling up hepatitis C testing and linkage-to-care among people who use drugs: lessons learned from a pilot project implemented at a supervised consumption siteAlannah Hannigan, Nandini Krishnan, Kirti Singh, et al.
Prostate Cancer and Prostatic Diseases|December 24, 2002
Combination gene therapy with adenoviral vector-mediated HSV-tk+GCV and IL-12 in an orthotopic mouse model for prostate cancerY Nasu, C H Bangma, G W Hull, et al.
BMC Infectious Diseases|March 1, 2017
Changes in mortality rates and causes of death in a population-based cohort of persons living with and without HIV from 1996 to 2012Oghenowede Eyawo, Conrado Franco-Villalobos, Mark W Hull, et al.
Plos One|March 17, 2026
Beyond direct-acting antiviral therapy: Characterizing mental health conditions and depressive symptoms among patients recently treated for hepatitis CSarah E Kelly, Adedayo Ajidahun, Shannon Bytelaar, et al.
Gene Therapy|August 6, 1999
Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic modelY Nasu, C H Bangma, G W Hull, et al.
AIDS (London, England)|April 5, 2019
Trends in cause-specific mortality in HIV-hepatitis C coinfection following hepatitis C treatment scale-upNadine Kronfli, Sahir R Bhatnagar, Mark W Hull, et al.
Plos One|September 7, 2019
Inflammatory biomarker levels over 48 weeks with dual vs triple lopinavir/ritonavir-based therapy: Substudy of a randomized trialDarrell H S Tan, Maria Jose Rolon, Maria Ines Figueroa, et al.
Journal of the International AIDS Society|September 15, 2016
Effects of a switch from tenofovir- to abacavir-based antiretroviral therapy, with or without atazanavir, on renal functionSilvia A Guillemi, Sean H Ling, Julia S Dahlby, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|March 11, 2022
Prevalence and incidence of hepatitis C infection amongst men who have sex with men in a population-based pre-exposure prophylaxis program in British Columbia, CanadaKyle A Thompson, Gabriel Blank, Junine Toy, et al.
Pageof 15